Last reviewed · How we verify

NCT05994586

The Efficacy of AP029 Mix in Patients With Impaired Carbohydrate Metabolism

Status unknown NA Last updated 16 August 2023
What this trial tests

NA trial testing AP029 mix in Diabetes in Adolescence in 30 participants. Status unknown.

Timeline
25 May 2023
Primary endpoint
26 November 2023
26 November 2023

Quick facts

Lead sponsorAronPharma Sp. z o. o.
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposesupportive care
Enrollment30
Start date25 May 2023
Primary completion26 November 2023
Estimated completion26 November 2023
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

AronPharma Sp. z o. o.

Who can join

Adults 18 to 75, any sex, with Diabetes in Adolescence or PreDiabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to demonstrate that a daily supplementation of AP029 Mix: I) has a positive effect on reducing side effects of metformin, while enhancing the therapeutic effect of metformin; II) normalizes prediabetes biomarkers in order to prevent further progression into diabetes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Development of Potential Therapeutic Agents from Black Elderberries (the Fruits of <i>Sambucus nigra</i> L.).
    Ren Y, Meyer G, Anderson AT, Lauber KM, et al · · 2024 · cited 2× · PMID 38998923 · DOI 10.3390/molecules29132971

Verify or expand the search:

Other recruiting trials for Diabetes in Adolescence

Currently open trials in the same condition.

Other AronPharma Sp. z o. o. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05994586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing